Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors
The sale came at $38.42 per share, slightly below the day's market close, as AtriCure maintains its $2.0 billion market cap in the medical device sector.
Overview
Maggie Yuen, a director at AtriCure, Inc. (NASDAQ:ATRC), reported a sale of 3,500 shares of common stock on August 5, 2026, according to a recent SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($38.42); post-transaction value based on August 05, 2026 market close ($39.34).
Details
AtriCure is a focused medical device company with a $2.0 billion market capitalization and $569.6 million in TTM revenue, positioning itself as a specialized provider of cardiac surgical solutions. The company maintains a differentiated product portfolio centered on radiofrequency ablation technology, which provides competitive advantages in the treatment of cardiac arrhythmias and related conditions. With a global distribution network spanning multiple continent, AtriCure has established itself as a significant player in the cardiac surgery device market.
Source
Originally published at www.fool.com.